Lorne E. Albrecht

Surrey, BC, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 21 publications

Longitudinal Performance of the Psoriasis Epidemiology Screening Tool (PEST) in Canada and Latin America: Results from the Prospective, Observational, 5-Year PURE Registry.

Longitudinal Performance of the Psoriasis Epidemiology Screening Tool (PEST) in Canada and Latin America: Results from the Prospective, Observational, 5-Year PURE Registry.

Journal: Dermatology and therapy

Published: April 20, 2026

Current Understanding of Seborrheic Dermatitis: Presentation, Diagnosis, and Special Populations.

Current Understanding of Seborrheic Dermatitis: Presentation, Diagnosis, and Special Populations.

Journal: Journal of cutaneous medicine and surgery

Published: September 18, 2025

Current Understanding of Seborrheic Dermatitis: Treatment Options.

Current Understanding of Seborrheic Dermatitis: Treatment Options.

Journal: Journal of cutaneous medicine and surgery

Published: September 18, 2025

Current Understanding of Seborrheic Dermatitis: Epidemiology, Burden of Disease, and Pathophysiology.

Current Understanding of Seborrheic Dermatitis: Epidemiology, Burden of Disease, and Pathophysiology.

Journal: Journal of cutaneous medicine and surgery

Published: September 18, 2025

Guselkumab for Moderate to Severe Scalp Psoriasis Across All Skin Tones: Cohort B of the VISIBLE Randomized Clinical Trial.

Guselkumab for Moderate to Severe Scalp Psoriasis Across All Skin Tones: Cohort B of the VISIBLE Randomized Clinical Trial.

Journal: JAMA dermatology

Published: June 25, 2025

Canadian Expert Consensus on the Use of Halobetasol Propionate/Tazarotene Lotion for Plaque Psoriasis.

Canadian Expert Consensus on the Use of Halobetasol Propionate/Tazarotene Lotion for Plaque Psoriasis.

Journal: Dermatology and therapy

Published: April 26, 2024

Effectiveness and safety of secukinumab updosing in patients with moderate to severe plaque psoriasis: data from the PURE registry.

Effectiveness and safety of secukinumab updosing in patients with moderate to severe plaque psoriasis: data from the PURE registry.

Journal: Archives of dermatological research

Published: March 28, 2024

Long-term safety and effectiveness of roflumilast cream 0.3% in adults with chronic plaque psoriasis: A 52-week, phase 2, open-label trial.

Long-term safety and effectiveness of roflumilast cream 0.3% in adults with chronic plaque psoriasis: A 52-week, phase 2, open-label trial.

Journal: Journal of the American Academy of Dermatology

Published: September 20, 2023

Sustained Effectiveness of Secukinumab Across Different Body Regions in Patients with Moderate-to-Severe Plaque Psoriasis from the PURE Registry.

Sustained Effectiveness of Secukinumab Across Different Body Regions in Patients with Moderate-to-Severe Plaque Psoriasis from the PURE Registry.

Journal: Dermatology and therapy

Published: October 06, 2022

Effect of Roflumilast Cream vs Vehicle Cream on Chronic Plaque Psoriasis: The DERMIS-1 and DERMIS-2 Randomized Clinical Trials.

Effect of Roflumilast Cream vs Vehicle Cream on Chronic Plaque Psoriasis: The DERMIS-1 and DERMIS-2 Randomized Clinical Trials.

Journal: JAMA

Published: September 20, 2022

Dermatologists' Perspectives on Defining Moderate Psoriasis: The Canadian Moderate Psoriasis Survey.

Dermatologists' Perspectives on Defining Moderate Psoriasis: The Canadian Moderate Psoriasis Survey.

Journal: Journal of drugs in dermatology : JDD

Published: February 04, 2021

Efficacy and safety of apremilast in patients with mild-to-moderate plaque psoriasis: Results of a phase 3, multicenter, randomized, double-blind, placebo-controlled trial.

Efficacy and safety of apremilast in patients with mild-to-moderate plaque psoriasis: Results of a phase 3, multicenter, randomized, double-blind, placebo-controlled trial.

Journal: Journal of the American Academy of Dermatology

Published: January 27, 2021

Showing 1-12 of 21

Last Updated: 09/26/2026